Open AccessAntitumor effects of Endostar on non-Hodgkin's lymphoma by regulating endothelial progenitor cells through protein kinase B-dependent pathway
Author(s) -
Dandan Yu,
Haijian Wu,
Bohan Yang,
Kunyu Yang,
Hongli Liu,
Gang Wu
Publication year - 2013
Publication title -
acta biochimica et biophysica sinica
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.771
H-Index - 57
eISSN - 1745-7270
pISSN - 1672-9145
DOI - 10.1093/abbs/gmt070
Subject(s) - cancer research , progenitor cell , lymphoma , mapk/erk pathway , in vivo , angiogenesis , kinase , progenitor , medicine , endothelial progenitor cell , biology , immunology , stem cell , microbiology and biotechnology
Endothelial progenitor cells (EPCs) play an important role in non-Hodgkin's lymphoma (NHL) development. Endostar is an anti-angiogenic drug designed to stop cancer by nullifying a tumor's ability to obtain oxygen and nutrients. In this study, we examined the anti-angiogenic activities of Endostar on NHL cell lines and murine xenograft model of NHL in vitro and in vivo, respectively, and explored the underlying antiangiogenic mechanism of Endostar. Results showed that Endostar may inhibit the EPC proliferation by reducing the expression of p-protein kinase B, but not p-ERK expression. Our finding could lead to a better understanding of the effects of Endostar on NHL.